NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

• Jiejie Xu,
• Yu Zhu,
• Zewei Wang,
• Han Zeng,
• Zhaopei Liu,
• Yuan Chang,
• Yiwei Wang,
• Le Xu,
• Kaifeng Jin,
• Fei Shao,
• Sen Yan

Affiliations

Jiejie Xu

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

Yu Zhu

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China

Zewei Wang

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China

Han Zeng

Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China

Zhaopei Liu

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China

Yuan Chang

Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China

Yiwei Wang

Department of Urology, Shanghai Ninth People`s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Le Xu

Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Kaifeng Jin

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

Fei Shao

Department of Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Sen Yan

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China